In conclusion, this study demonstrated excellent negative predictive value of iBE and agreement between iBE and CBE as triage tests for the detection of clinically relevant breast lesions.

iBreastExam identified 15 women with a correlating BIRAD 4 score, of which 3 were confirmed as early-stage breast cancers (Stage IIA, IA and DCIS), none with palpable abnormality on clinical breast examination.

97% of the participants reported the test as acceptable and recommendable to relatives and 98% expressed an interest to have iBreastExam made available at local Public Health Centers.

This validation study demonstrated excellent sensitivity of iBE for the identification of clinically significant lesions in patients presenting for diagnostic imaging.

Identified abnormalities in all 39 patients who presented with breast abnormalities and did not demonstrate any false negatives that would prevent the patients from additional evaluation, which makes it a good prescreening tool.

iBreastExam demonstrated significantly (23%) higher sensitivity and moderately (9%) higher specificity to detect breast lesions as compared to CBE. Lower FP rates compared to CBE reduces the pool of women requiring further diagnostic follow-up. iBreastExam requires minimal training and provides objective breast examination with digital documentation